Home » Science and Research Articles » Henry Rodriguez, Director of Clinical Proteomic Technologies for Cancer at the National Cancer Institute to Present at GTCbio's 2nd Rediscovering Biomarkers conference on July 10-11, 2008 in Boston, MA
Henry Rodriguez, Director of Clinical Proteomic Technologies for Cancer at the National Cancer Institute to Present at GTCbio's 2nd Rediscovering Biomarkers conference on July 10-11, 2008 in Boston, MA
Henry Rodriguez, Director of Clinical Proteomic Technologies for Cancer at the National Cancer Institute, NIH will be presenting at GTCbio's Rediscovering Biomarkers conference on July 10-11, 2008 in Boston, MA. Dr. Rodriguez will speak on removing bottle necks from proteomic process.
/Science and Research PR News/ - MONROVIA, CA, April 18, 2008 - Dr. Henry Rodriguez, Director of Clinical Proteomic Technologies for Cancer at the National Cancer Institute, NIH will be presenting at GTCbio's 2nd Annual Rediscovering Biomarkers conference on July 10-11, 2008 in Boston, MA. Dr. Rodriguez will speak on removing bottlenecks from proteomic process.
Proteomics have revolutionized cell biology and biochemistry by providing powerful new tools to characterize complex proteomes, multiprotein complexes and posttranslational modifications. Although proteomics technologies could address important problems in clinical and translational cancer research, attempts to use proteomics approaches to discover cancer biomarkers in biofluids and tissues have been largely unsuccessful and have engendered considerable skepticism. The National Cancer Institute has taken a leading role in facilitating the translation of proteomics from research to clinical application, through its Clinical Proteomic Technologies for Cancer initiative (CPTC) (http://proteomics.cancer.gov). The goal of the CPTC is to accelerate discovery and clinical research in cancer using an integrated approach that assesses and optimizes proteomic technology measurement capabilities and develops universally accepted metrics that identify and minimize experimental variability from run to run, instrument to instrument, and lab to lab. This program will enable the transition of proteomics technologies from basic research tools to reliable and robust clinical research platforms.
The 2nd Annual Rediscovering Biomarkers Conference will exposes attendees to the latest advancements and developments in biomarkers and predictive medicine. Attendees will gain insight into discovery and development processes, hear about new biomarkers and upcoming trends in the industry, as well as the status of those in clinical trials. Delegates will also receive highly valuable information on tools for improving reimbursement strategies and the efficacy and validation of biomarkers.
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=124
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
christy.bowman@gtcbio.com
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com |
|
|
Press Release Contact Information:
Rania Hafez
GTCbio
Marketing Director
434 W. Foothill Blvd.
Monrovia, CA
USA 91106
Voice: 626-256-6405
Fax: 626-256-6460
Website: Visit Our Website |
|
|
|
|
| SCIENCE AND RESEARCH ARCHIVE SEARCH |
|
|
| |
| SUBMIT SCIENCE AND RESEARCH NEWS |
|
|
| |
|
|
Advertise With Us |
About Us |
Contact Us